{
    "clinical_study": {
        "@rank": "28667", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive gemcitabine IV over 1-2.5 hours on days 1 and 8 and flavopiridol IV continuously over 24 hours on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\nCohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase I trial to study the effectiveness of gemcitabine plus flavopiridol in treating\n      patients who have advanced solid tumors. Drugs used in chemotherapy use different ways to\n      stop tumor cells from dividing so they stop growing or die. Combining more than one drug may\n      kill more tumor cells."
        }, 
        "brief_title": "Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "October 2010", 
            "@type": "Actual"
        }, 
        "condition": "Unspecified Adult Solid Tumor, Protocol Specific", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the maximum tolerated dose of gemcitabine and flavopiridol in patients with\n      advanced solid tumors.\n\n      II. Determine the toxicity and safety profile of this regimen in these patients.\n\n      III. Determine the pharmacokinetic profile of this regimen in this patient population.\n\n      OUTLINE: This is a dose-escalation study.\n\n      Patients receive gemcitabine IV over 1-2.5 hours on days 1 and 8 and flavopiridol IV\n      continuously over 24 hours on days 2 and 9. Courses repeat every 21 days in the absence of\n      disease progression or unacceptable toxicity.\n\n      Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the\n      maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at\n      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.\n\n      PROJECTED ACCRUAL: Approximately 6-58 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven solid tumor for which gemcitabine is a treatment option or for\n             which no effective therapy exists\n\n          -  Previously untreated disease allowed\n\n          -  No large and potentially symptomatic pericardial effusion or undrained pleural\n             effusion (with or without pleurodesis)\n\n          -  No CNS metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  At least 12 weeks\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 2,000/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  No prior thrombotic events\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  SGOT no greater than 2 times upper limit of normal\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n        Cardiovascular:\n\n          -  No clinically significant cardiac disease\n\n          -  No prior deep venous thrombus\n\n          -  No prior arterial vascular event\n\n          -  No prior myocardial infarction\n\n          -  No unstable angina\n\n          -  No prior transient ischemic attack or cerebrovascular accident\n\n          -  No cardiac arrhythmias that could be related to cardiac ischemia\n\n        Pulmonary:\n\n          -  No clinically significant pulmonary disease\n\n          -  No history of pulmonary embolism\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No active infection\n\n          -  No severe malnutrition or intractable emesis\n\n          -  No chronic diarrheal disease within the past 6 months\n\n        PRIOR CONCURRENT THERAPY:\n\n        Chemotherapy:\n\n          -  No more than 1 prior chemotherapy regimen\n\n          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and\n             recovered\n\n          -  Prior gemcitabine or flavopiridol allowed\n\n          -  No other concurrent chemotherapy\n\n        Radiotherapy:\n\n          -  At least 3 weeks since prior radiotherapy and recovered\n\n          -  No prior radiotherapy to more than 50% of bone marrow\n\n          -  No concurrent radiotherapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00007917", 
            "org_study_id": "00-166", 
            "secondary_id": [
                "U01CA062490", 
                "P30CA006516", 
                "DFCI-00166", 
                "NCI-24", 
                "CDR0000068344"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I", 
                "intervention_name": "alvocidib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm I", 
                "intervention_name": "gemcitabine hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Flavopiridol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "unspecified adult solid tumor, protocol specific", 
        "lastchanged_date": "February 27, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DFCI-00166"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Trial Of Gemcitabine Followed By Flavopiridol In Patients With Solid Tumors", 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Geoffrey Shapiro, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2010", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00007917"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }, 
    "geocoordinates": {
        "Dana-Farber Cancer Institute": "42.358 -71.06", 
        "Massachusetts General Hospital Cancer Center": "42.358 -71.06"
    }
}